Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27493134 | 0.88 | POLB (0.68) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL4256224 | 0.81 | KMT2A (0.53) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL7117183 | 0.80 | ALDH1A1 (0.59) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL15672851 | 0.79 | MEN1 (0.58) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL3367299 | 0.79 | PRMT1 (0.54) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL4520702 | 0.79 | POLB (0.79) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL4601440 | 0.79 | CA1 (0.59) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL1414871 | 0.79 | CA1 (0.67) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL21034352 | 0.79 | TAAR1 (0.59) | ALDH1A1MAPTKDM4ELMNACYP3A4 | |
| SCHEMBL229506 | 0.78 | CA12 (0.68) | ALDH1A1KDM4ELMNACYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1693372-A1 | Novel Sulfamides and their use as endothelin receptor antagonists | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | claimed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | claimed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | claimed |
| US-7018983-B2 | Treatment of migraine | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2006-03-28 | — | — | US | claimed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | claimed |
| EP-1345920-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-09-24 | — | — | EP | claimed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | claimed |
| US-9175006-B2 | Compositions and methods for cyclofructans as separation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-11-03 | — | — | US | disclosed |
| US-20110024292-A1 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-02-03 | — | — | US | disclosed |
| WO-2003082263-A1 | SULFAMIC ACIDS AS INHIBITORS OF HUMAN CYTOPLASMIC PROTEIN TYROSINE PHOSPHATASES | ONTOGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-0801642-B1 | NOVEL SULFAMATE COMPOUND CONTAINING N-SUBSTITUTED CARBAMOYL GROUP AND METHOD FOR PREPARING THE SAME | YUKONG LTD (KR) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5654461-A | Sulfamate compound containing carbamoyl group | YUKONG LIMITED (KR) | 1997-08-05 | — | — | US | disclosed |
| WO-1997016417-A1 | NOVEL SULFAMATE COMPOUND CONTAINING CARBAMOYL GROUP | YUKONG LIMITED (KR) | 1997-05-09 | — | — | WO | disclosed |
| US-4792569-A | TREATING EPILEPSY, GLAUCOMA | MCNEILAB, INC. (US) | 1988-12-20 | — | — | US | disclosed |
| US-4001241-A | GASTRIC ACID, ANTISECRETORY AGENTS | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3966945-A | 2-Alkoxy(and 2-alkoxyalkyl)-2-heterocyclic-thioacetamides for inhibiting gastric acid secretion | SMITHKLINE CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
| US-3956494-A | ANTISECRETORY AGENTS, HETEROCYCLIC THIOPROPIONAMIDES | SMITHKLINE CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3948892-A | 2-Alkoxy(and 2-amino)-3-amino-2-heterocyclic-thiopropanamides | SMITHKLINE CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110024292-A1 | COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS | PAICS, DCXR, PFAS | ALDH1A1 1565/4885MAPT 1797/4885KDM4E 4235/4885 |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | ALDH1A1 4258/4885MAPT 4294/4885KDM4E 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.